bit.bio announces cell therapy pipeline and expanded Scientific Advisory Board

Portfolio company bit.bio, the company coding human cells for novel cures, announced its cell therapy pipeline, and declared its lead cell therapy candidate as it prepares to enter clinical development in 2025. The company also announced three key additions to its Scientific Advisory Board.